RELIEF THERAPEUTICS HLDG - RLFTF STOCK NEWS

Relief Therapeutics has increased its registered share capital from 3,246,727,248 to 3,371,727,248 shares, issuing 125,000,000 new shares at CHF 0.01 each. These shares, subscribed by Relief Therapeutics International SA, will be listed on the SIX Swiss Exchange around March 11, 2021, allowing for greater financial flexibility. The company is focused on developing RLF-100^TM (aviptadil) for severe COVID-19 cases, currently in late-stage clinical trials.

Relief Therapeutics announced updates on its lead compound RLF-100(TM) (aviptadil), which is in advanced clinical trials for treating respiratory failure in critical COVID-19 patients. Data from a Phase 2b/3 trial, managed by NeuroRx, indicates that RLF-100(TM) has shown promising results, significantly accelerating patient recovery. The company holds various patents for the drug and focuses on clinical-stage programs for respiratory diseases. It is publicly traded under the symbols RLF in Switzerland and RLFTF in the U.S.

NeuroRx announced positive interim results for ZYESAMI™ (aviptadil) in a Phase 2b/3 trial for treating respiratory failure in critically ill Covid-19 patients. The drug showed a 35% higher likelihood of recovery by day 28 compared to placebo, with a median 10-day acceleration in recovery time. As High Flow Nasal Oxygen becomes the main treatment for such patients, NeuroRx plans to apply for Emergency Use Authorization if positive trends continue. The trial involved 10 U.S. hospitals and is part of a collaboration with RELIEF THERAPEUTICS. NeuroRx is also completing a business combination with Big Rock Partners Acquisition Corporation (BRPA).

On February 9, 2021, NeuroRx and Relief Therapeutics announced preliminary results from the Phase 2b/3 trial of ZYESAMI™ in COVID-19 patients experiencing respiratory failure. The trial indicated significant improvements for patients receiving ZYESAMI compared to those on placebo, including earlier hospital discharge and reduced ICU time. The data suggests a potential Emergency Use Authorization submission for ZYESAMI, indicating its importance as the first drug specifically targeting critically ill COVID-19 patients. However, primary endpoint results are still pending.

Relief Therapeutics Holding AG announced the immediate resignation of board member Thomaz Burckhardt, who is stepping down to focus on other professional interests. Chairman Raghuram Selvaraju expressed gratitude for Burckhardt's contributions. The company is seeking candidates to fill the vacancy with individuals who have substantial experience in life sciences and healthcare. Relief continues to prioritize its clinical-stage programs, notably RLF-100^TM, currently being tested for respiratory issues related to COVID-19.

Relief Therapeutics announced the initiation of a phase 2/3 trial for inhaled RLF-100(TM) to treat severe COVID-19 patients, in collaboration with UCI Health. The trial aims to determine if RLF-100(TM) can prevent progression to critical illness. Additionally, top-line data from a previous phase 2b/3 trial of intravenous RLF-100(TM) is expected to be released this month after ongoing statistical analyses. Relief's focus is on developing treatments for respiratory diseases based on clinically tested molecules.

Relief Therapeutics is holding an Extraordinary General Meeting (EGM) for shareholders on December 17, 2020, due to COVID-19 restrictions. Shareholders registered by December 4, 2020, can vote through an independent proxy. Key agenda items include the election of Tom Plitz to the Board of Directors, compensation adjustments for the Board and Executive Committee, and increases in authorized and conditional share capital. These changes aim to enhance the company's flexibility for future financing and development of its lead compound, RLF-100^TM, targeting severe COVID-19 cases.

Relief Therapeutics, in collaboration with NeuroRx, has enrolled 150 patients in a phase 2b/3 trial for RLF-100(TM), targeting respiratory failure in critical COVID-19 cases. The trial aims to assess the drug's effectiveness, with no serious adverse events reported thus far. An earlier study indicated a significant survival advantage linked to RLF-100(TM). Additionally, main shareholder GEM has exercised 500 million warrants, increasing Relief's cash balance to approximately CHF 49.8 million.